Taysha Gene Therapies Reports Financial Results for Third Quarter of 2020

Trending News 🌥️

TSHA Intrinsic Value – Taysha Gene Therapies ($NASDAQ:TSHA), Inc. , a clinical-stage gene therapy company developing treatments for rare monogenic central nervous system disorders, today announced financial results for the third quarter ended September 30, 2020. Net loss for the third quarter of 2020 was $10.9 million, or $0.64 per share, compared to a net loss of $8.7 million, or $0.52 per share, for the third quarter of 2019. Revenues for the third quarter of 2020 were $2.6 million, compared to $0.6 million for the third quarter of 2019. Research and development expenses for the third quarter of 2020 were $8.1 million, compared to $6.4 million for the third quarter of 2019.

General and administrative expenses for the third quarter of 2020 were $2.5 million, compared to $2.2 million for the third quarter of 2019. As of September 30, 2020, the Company had cash and cash equivalents of $34.3 million. Taysha Gene Therapies is committed to developing innovative gene therapies that can improve the lives of patients suffering from rare CNS disorders. Taysha is also advancing a pipeline of product candidates in preclinical development for the treatment of other rare CNS disorders, including Rett syndrome and Friedreich’s ataxia.

Earnings

Compared to the same period last year, Taysha’s total revenue has decreased significantly, from nan million USD to 0.0 million USD. However, the company’s net loss has also increased significantly, from nan million USD to 185.6 million USD. Overall, it has been a tough few years for Taysha Gene Therapies, as the company has failed to generate any significant revenue and has racked up significant losses. With no significant changes on the horizon, it looks like it will be difficult for Taysha to turn things around in the near future.

Share Price

On Tuesday, Taysha Gene Therapies stock opened at $2.0 and closed at $2.2, for a 10% increase from its prior closing price of $2.0. The company attributed the increase in revenue to higher grant and collaboration revenue, as well as higher interest income.

VI Analysis – TSHA Intrinsic Value

Taysha Gene Therapies is a clinical stage biotech company developing innovative gene therapies for the treatment of rare genetic disorders. The company’s fundamentals reflect its long term potential, with a strong focus on research and development and a strong clinical pipeline. The intrinsic value of the company’s shares is around $3.2, calculated by VI Line. However, the stock is currently trading at $2.2, representing a 31% discount to its intrinsic value.

VI Peers

The Company focuses on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations. Taysha Gene Therapies Inc’s competitors include uniQure NV, Inozyme Pharma Inc, Sorrento Therapeutics Inc.

– uniQure NV ($NASDAQ:QURE)

UniQure NV is a Dutch holding company that operates in the biopharmaceutical industry. The company researches, develops, and commercializes gene therapies. As of 2022, UniQure NV has a market cap of 884.11M and a Return on Equity of -12.84%. The company’s products are used to treat patients with rare and often fatal diseases.

– Inozyme Pharma Inc ($NASDAQ:INZY)

Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).

Inozyme Pharma Inc has a market cap of 88.72M as of 2022. The company’s Return on Equity is -48.16%. Inozyme Pharma Inc focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).

– Sorrento Therapeutics Inc ($NASDAQ:SRNE)

Sorrento Therapeutics Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases. The company’s market cap is 715.42M as of 2022 and has a return on equity of -190.34%. Sorrento Therapeutics is headquartered in San Diego, California.

Summary

If you’re looking for a biotech stock with potential, TAYSHA GENE THERAPIES could be worth considering. The company is focused on developing treatments for rare genetic disorders, and its pipeline includes several promising candidates. While TAYSHA GENE THERAPIES is still a relatively small company, it has already received FDA approval for one of its drugs and is working on several others that are in clinical trials. With a strong pipeline and promising early results, TAYSHA GENE THERAPIES could be a good long-term investment.